Skip to nav Skip to content

CAR T-cell therapy has revolutionized the treatment of refractory lymphoma. This groundbreaking immunotherapy also shows great promise for treating other types of blood cancer as well as certain solid tumors. As a world-renowned pioneer of many novel cancer therapies, Moffitt Cancer Center is spearheading the development of CAR-T clinical trials nationwide. Working in conjunction with cancer centers across the U.S., we have achieved many significant research breakthroughs and continue to make progress in our fight against cancer every single day.

Moffitt is especially proud to have made Yescarta available to the first patient in the world following its approval by the U.S. Food and Drug Administration (FDA). Yescarta is only the second gene therapy to be approved by the FDA as well as the first treatment of its kind to be approved for treating certain types of non-Hodgkin lymphoma.

Progress through collaboration

Many cellular therapy trials, including CAR T clinical trials, are available exclusively through Moffitt. For information about our current research studies that are accepting new patients, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form. If you have a patient who could potentially benefit from one of our promising CAR T clinical trials, you can refer him or her to our Blood and Marrow Transplant and Cellular Immunotherapy Program by completing our online form or contacting a physician liaison for assistance. We can provide individualized guidance to help you find the best treatment options.

CAR T-cell therapy is a complex process, and you can feel confident that your patient will receive competent and committed treatment and support while under the care of the multispecialty team at Moffitt. You can also expect to receive timely and informative updates from us on your patient’s progress. It is our privilege to collaborate with referring physicians. Working together, we can improve outcomes and quality of life for our shared patients.